series-a
Stage
1
Investors
About
Ability develops fully-human precision biotherapeutic antibodies using its proprietary AI-driven discovery platform AbiLeap™ to target specific immune cell subpopulations for autoimmune, inflammatory diseases, and cancer therapies.
Explore Ability's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.